Squarepoint’s Precision BioSciences DTIL Stock Holding History

Squarepoint’s Portfolio DTIL Stock Details DTIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$188K	Sell	30,064 -107,042	-78%	-$809K	﹤0.01%	4090
2026 Q2	$1.08M	Buy	137,106 +93,258	+213%	+$656K	﹤0.01%	2844
2026 Q1	$241K	Buy	+43,848	New	+$202K	﹤0.01%	3853
2025 Q1	–	Sell	-46,929	Closed	-$179K	–	4774
2024 Q4	$179K	Buy	+46,929	New	+$343K	﹤0.01%	4511
2023 Q4	–	Sell	-3,385	Closed	-$34.7K	–	4098
2023 Q3	$34.7K	Buy	+3,385	New	+$52K	﹤0.01%	3665
2022 Q2	–	Sell	-769	Closed	-$71K	–	2988
2022 Q1	$71K	Buy	769 +15	+2%	+$2.04K	﹤0.01%	2651
2021 Q4	$167K	Buy	754 +404	+115%	+$113K	﹤0.01%	2779
2021 Q3	$121K	Buy	+350	New	+$119K	﹤0.01%	2628
2021 Q1	–	Sell	-2,108	Closed	-$527K	–	3224
2020 Q4	$527K	Buy	2,108 +528	+33%	+$129K	﹤0.01%	1774
2020 Q3	$292K	Buy	+1,580	New	+$314K	﹤0.01%	1814
2020 Q2	–	Sell	-632	Closed	-$114K	–	2292
2020 Q1	$114K	Sell	632 -2,242	-78%	-$587K	﹤0.01%	1615
2019 Q4	$1.2M	Buy	2,874 +1,480	+106%	+$465K	0.01%	1228
2019 Q3	$351K	Buy	+1,394	New	+$454K	﹤0.01%	1809

Other funds holding DTIL

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Squarepoint's DTIL Position: Q3 2026 in Review

Squarepoint reduced its Precision BioSciences (DTIL) stake by 78% in Q3 2026, selling an estimated $809K and leaving 30,064 shares worth $188K. The position accounts for ﹤0.01% of the portfolio, ranked #4090.

Squarepoint first reported a position in DTIL in Q3 2019 and has held it in 13 quarters since. The position peaked at $1.2M in Q4 2019. 46 funds tracked by Wall St. Rank hold DTIL as of Q3 2026.

Squarepoint held 30,064 shares of Precision BioSciences worth $188K as of Q3 2026.
Squarepoint sold 107,042 Precision BioSciences shares in Q3 2026, an estimated $809K.
Precision BioSciences made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #4090 holding.
Squarepoint first reported a position in Precision BioSciences in Q3 2019 and has held it in 13 quarters since.
Squarepoint's Precision BioSciences position peaked at $1.2M in Q4 2019.
46 funds tracked by Wall St. Rank held Precision BioSciences as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.